Estradiol Gel (Divigel/Elestrin) Side Effects: Incidence Rates Across Trials

What Is Estradiol Gel and Who Is It For?

Estradiol gel delivers 17-beta estradiol through the skin, reaching systemic circulation without first-pass liver metabolism. Two branded products are available in the United States: Divigel 0.1% and Elestrin 0.06%. Both are FDA-approved specifically for moderate-to-severe vasomotor symptoms (hot flashes, night sweats) of menopause.

The gel is applied once daily to skin areas such as the thigh or upper arm. Because estradiol is absorbed transdermally, serum levels are lower and more stable than with oral estradiol, which matters for women who have cardiovascular or clotting risk factors. Oral estrogen raises hepatic production of clotting factors and sex hormone-binding globulin; transdermal routes largely bypass that first-pass effect.

Who uses estradiol gel in clinical practice?

In clinical practice, estradiol gel is most often prescribed to:

• Perimenopausal and postmenopausal women with bothersome vasomotor symptoms
• Women who cannot tolerate oral estrogen due to GI side effects or who prefer a non-oral route
• Women with elevated triglycerides, since transdermal estradiol does not raise triglycerides the way oral preparations can
• Women at higher risk for gallbladder disease, as oral estrogen roughly doubles that risk while transdermal data are more reassuring

Women who still have a uterus must add a progestogen to protect the endometrium. Women who have had a hysterectomy can use estrogen alone.

How Common Are Side Effects? Trial-by-Trial Breakdown

The best incidence data come from the two key Phase III randomized controlled trials submitted for FDA approval, plus post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS).

Divigel Phase III trial (Bachmann et al., 2009)

The key Divigel study was a 12-week, multicenter, double-blind, placebo-controlled trial enrolling 495 postmenopausal women with at least 7 moderate-to-severe hot flashes per day. Participants were randomized to Divigel 0.25 g/day, 0.5 g/day, 1.0 g/day, or placebo. Bachmann et al., 2009, Menopause showed significant reductions in hot-flash frequency and severity at both the 0.5 g and 1.0 g doses by week 12.

Adverse event incidence in the Divigel trial at the 0.5 g/day and 1.0 g/day doses combined:

| Adverse Event | Divigel (any dose) | Placebo | |---|---|---| | Breast tenderness | ~10% | ~4% | | Headache | ~8% | ~6% | | Nasopharyngitis | ~6% | ~5% | | Application-site reactions (erythema, pruritus) | ~5% | ~2% | | Nausea | ~3% | ~2% | | Back pain | ~4% | ~4% | | Vaginal bleeding/spotting | ~3% | <1% |

Breast tenderness was dose-dependent: it was lower at the 0.25 g/day dose (~5%) and highest at the 1.0 g/day dose (~12%). Serious adverse events occurred in <2% of participants and were not considered drug-related by investigators.

Elestrin Phase III trial

The key Elestrin trial was also a 12-week, double-blind, placebo-controlled study. The Elestrin prescribing information documents the following adverse events occurring at an incidence of ≥5% in the active arm:

• Upper respiratory tract infection: ~8%
• Breast pain/tenderness: ~7%
• Headache: ~6%
• Arthralgia: ~5%

Application-site reactions with Elestrin (which contains a different gel base with aloe vera) were reported in approximately 3% of active-arm participants, somewhat lower than Divigel. The difference likely reflects formulation, not the estradiol itself.

What the FAERS post-marketing data show

Post-marketing FAERS reports for estradiol transdermal products filed between 2007 and 2023 most frequently mention:

• Breast tenderness or pain
• Headache
• Mood changes (irritability, depression-like symptoms)
• Vaginal bleeding
• Skin reactions at the application site

FAERS data are limited by voluntary reporting and cannot establish incidence rates. They are most useful for signal detection of rare events. Reports of contact transfer (estradiol transferred to a partner or child through skin contact) appear in FAERS for all transdermal estrogen products, making hand-washing and covering the application site important steps you should follow after application.

Side Effects by Body System

Breast effects

Breast tenderness is the single most commonly reported side effect. It is estrogen-driven, occurs because estrogen stimulates breast glandular tissue, and tends to peak in the first 4-8 weeks of therapy before subsiding as tissues adapt. If you develop new breast pain that is persistent, asymmetric, or associated with a lump, that requires clinical evaluation rather than watchful waiting.

Breast density increases with estrogen therapy. The Women's Health Initiative (WHI) estrogen-plus-progestin arm found that combination hormone therapy increased breast cancer risk by approximately 26% (hazard ratio 1.26, 95% CI 1.00-1.59) over 5.6 years. Estrogen-alone therapy in WHI (women with prior hysterectomy) did not significantly increase breast cancer risk at 7 years (HR 0.77, 95% CI 0.59-1.01). Because estradiol gel is systemic, these class-level risks are relevant even though WHI used conjugated equine estrogen, not estradiol gel specifically.

Cardiovascular and clotting effects

Transdermal estradiol has a more favorable cardiovascular profile than oral estradiol in most observational data. A large nested case-control study from the CPRD UK database (Vinogradova et al., 2019, BMJ) found that oral estrogen-only therapy was associated with an odds ratio for VTE of 1.58 (95% CI 1.48-1.69), while transdermal estradiol was associated with an odds ratio of 0.93 (95% CI 0.87-1.01), meaning no significantly elevated clot risk. This distinction is clinically meaningful for women who have a personal or family history of deep vein thrombosis.

Stroke risk with transdermal estradiol also appears lower than with oral preparations in observational data, though the absolute risk remains small in younger postmenopausal women (within 10 years of menopause onset).

Neurological effects: headache and migraine

Headache is reported in roughly 6-8% of estradiol gel users across trials. For women with a history of migraine, the relationship between estrogen and migraine is complex. Estrogen withdrawal, not steady estrogen, typically triggers menstrual migraine. A stable transdermal estradiol level may therefore be better tolerated than oral estradiol, which produces larger serum peaks and troughs. If you experience new or worsening migraine after starting estradiol gel, discuss whether the dose or regimen needs adjustment rather than stopping abruptly.

Mood and psychological effects

Mood changes are not well-captured in short 12-week trials because they may emerge over months. ACOG Practice Bulletin No. 141 on menopausal hormone therapy acknowledges that estrogen can have mood-stabilizing effects for many perimenopausal and postmenopausal women, particularly those whose low mood is driven by vasomotor symptoms disrupting sleep. However, some women report irritability or low mood on estrogen therapy.

If you have a history of hormone-sensitive mood disorder (premenstrual dysphoric disorder, postpartum depression, or perimenopausal depression), tracking your mood systematically in the first 3 months of therapy is a practical strategy for distinguishing estrogen-driven effects from unrelated mood changes.

Application-site reactions

Application-site erythema, pruritus (itching), and rash occur in roughly 3-7% of users across trials. Strategies to reduce site reactions include:

• Rotating the application site daily
• Applying to clean, dry skin (wait 5 minutes after bathing)
• Avoiding application immediately after shaving
• If pruritus is persistent, ask your clinician about switching to Elestrin, which uses a different base, or trying a different transdermal formulation

True contact dermatitis to estradiol itself is uncommon; most reactions are to the gel vehicle.

Vaginal and uterine effects

Vaginal spotting or bleeding occurs in approximately 3% of estradiol gel users in the trial data. If you have not had a hysterectomy and experience any vaginal bleeding while on estrogen therapy without a progestogen, this requires prompt evaluation to rule out endometrial hyperplasia or carcinoma. Endometrial protection requires adequate progestogen opposition, and the dose and type of progestogen matters.

For women already on combined therapy (estrogen plus progestogen), breakthrough bleeding in the first 3-6 months is common as the endometrium adjusts. Bleeding that starts after 6 months of continuous combined therapy, or that is heavy, should be evaluated.

Rare and Serious Adverse Events

Rare but serious adverse events associated with systemic estrogen therapy as a class include:

Venous thromboembolism (VTE). As noted above, transdermal estradiol carries a much lower VTE signal than oral estradiol. The absolute risk in healthy postmenopausal women under 60 is low.

Gallbladder disease. Oral estrogen doubles gallbladder disease risk. Transdermal estradiol data from the ESTHER study (Canonico et al., 2010, Circulation) suggest a more neutral effect on coagulation and likely gallbladder risk, though direct gallbladder-specific data for transdermal gel specifically are limited.

Endometrial cancer. Unopposed estrogen in women with a uterus significantly increases endometrial cancer risk; the relative risk is approximately 2- to 12-fold depending on duration and dose. Adding an adequate progestogen eliminates most of this excess risk. ACOG Practice Bulletin No. 149 notes that the risk returns toward baseline within a few years of stopping unopposed estrogen.

Breast cancer (class). See the breast effects section above.

Ovarian cancer. Long-term estrogen use (more than 10 years) has been associated with a modest increase in ovarian cancer risk in some studies. The absolute numbers are small.

A practical way to think about serious risks is to separate the transdermal route from the class:

1. Risks that appear lower with transdermal vs. Oral routes: VTE, stroke, triglyceride elevation, gallbladder disease, blood pressure elevation
2. Risks that remain a class effect regardless of route: endometrial cancer (from unopposed estrogen), breast cancer (with long-term use plus progestogen), ovarian cancer (long-term)

This framework helps you weigh whether switching routes addresses your concern or whether the risk requires stopping hormone therapy entirely.

Life-Stage Differences in Side Effects

Perimenopause

Women in perimenopause still have ovarian function and may have irregular cycles. Estradiol gel is not formally approved for perimenopausal women with intact ovulatory cycles. If you are perimenopausal and prescribed estradiol gel off-label, be aware that:

• Exogenous estradiol on top of variable endogenous estrogen production may cause more pronounced breast tenderness and bloating
• Vaginal bleeding is harder to interpret because irregular periods are expected in perimenopause
• You are not reliably protected from pregnancy by estrogen therapy alone

Early postmenopause (under age 60, within 10 years of final period)

The 2022 Menopause Society position statement states that for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy for vasomotor symptoms generally outweigh the risks. Side effects in this group tend to be the common and manageable ones (breast tenderness, headache) rather than serious events.

Late postmenopause (over age 60 or more than 10 years from final period)

Initiating systemic estrogen therapy in this group carries higher absolute cardiovascular and stroke risk. Side effects in terms of tolerability are similar, but the benefit-risk balance shifts. If you are in this life stage and considering starting estradiol gel, the conversation with your clinician needs to include cardiovascular risk stratification.

Pregnancy, Lactation, and Contraception (Required Section)

Pregnancy: Contraindicated. Do not use.

Estradiol gel is contraindicated in pregnancy. The FDA Divigel label carries a clear contraindication for use in pregnancy. Exogenous estrogen exposure in the first trimester has been associated with congenital urogenital abnormalities in some older epidemiologic data, though the absolute risk from brief exposure is uncertain. If you discover you are pregnant while using estradiol gel, stop the gel and contact your obstetric provider.

Lactation: Not recommended.

Estradiol is present in breast milk, and exogenous estrogen suppresses prolactin-mediated milk production. The Elestrin label states that the drug is not recommended during lactation. Women who are postpartum and breastfeeding should not use systemic estradiol for vasomotor symptoms. If postpartum hot flashes are causing significant distress during lactation (which can occur as a result of hypoestrogenism while breastfeeding), discuss non-hormonal options with your provider.

Contraception:

Estradiol gel does not provide contraception. If you are perimenopausal and still at risk of pregnancy (last menstrual period within the past 12 months, or any uncertainty about ovulatory status), you need reliable contraception in addition to any hormone therapy. Low-dose combined oral contraceptives or a levonorgestrel-releasing IUD can serve dual purposes in perimenopause: managing vasomotor symptoms and providing contraception.

Contact transfer is a separate concern. If estradiol gel is applied and another person (including a breastfed infant) touches the application site before the gel dries, they can absorb estradiol. Premature breast development and precocious puberty have been reported in children with repeated exposure to adult transdermal estrogen products via FAERS. Cover the application site or wash hands thoroughly after application.

Who This Is Right For and Who Should Avoid It

Good candidates for estradiol gel

• Postmenopausal women with bothersome vasomotor symptoms (7 or more moderate-to-severe hot flashes per day, or fewer if they significantly disrupt sleep or quality of life)
• Women who cannot tolerate oral estrogen GI side effects
• Women with elevated triglycerides or a history of hypertriglyceridemia (oral estrogen raises triglycerides; transdermal does not)
• Women with personal or family history of VTE who need estrogen therapy (transdermal route is preferred per The Menopause Society guidelines)
• Women with migraine history who have tried oral estrogen without success

Women who should avoid estradiol gel or use it with extreme caution

• Active or recent VTE (within 12 months), regardless of route
• Known or suspected estrogen-receptor-positive breast cancer or personal history of breast cancer
• Pregnancy (absolute contraindication)
• Active or recent arterial thromboembolic disease (stroke, MI)
• Unexplained vaginal bleeding without evaluation
• Liver dysfunction (though transdermal route does partially spare the liver, systemic levels are still achieved)
• Known hypersensitivity to any component of the gel

Women with PCOS who are in perimenopause and still menstruating irregularly represent a specific subgroup where estradiol gel decisions are complicated. Exogenous estrogen is generally not needed if endogenous estrogen levels are adequate, and adding estrogen without proper endometrial protection in a woman with anovulatory cycles and potential endometrial hyperplasia from unopposed endogenous estrogen is a meaningful risk.

How Side Effects Compare Across Transdermal Estradiol Formulations

Women sometimes ask whether switching from gel to patch or to spray changes the side-effect profile. Across transdermal formulations, the estradiol-related systemic side effects (breast tenderness, headache, mood effects) are driven by the achieved serum estradiol level, not the delivery vehicle. What differs is:

• Skin reactions. Patches have higher rates of adhesive-related skin reactions (5-15% in patch trials) than gels. Gels have lower application-site reaction rates overall.
• Dosing flexibility. Gels allow dose titration by pump actuation or packet size. Patches come in fixed doses.
• Compliance. Some women prefer daily gel application over twice-weekly patch changes; others find the reverse.

The 2022 Menopause Society position statement does not preferentially recommend one transdermal formulation over another for efficacy; selection should be based on tolerability, cost, and individual preference.

Managing and Reducing Side Effects

Most common side effects are manageable without stopping therapy. Strategies backed by clinical practice include:

Breast tenderness. Consider dose reduction if you are on 1.0 g/day Divigel and tolerating it otherwise. Give tenderness 8-12 weeks to resolve before concluding it will persist. Wearing a supportive bra and reducing caffeine intake (a commonly reported clinical observation, though not proven in RCTs) may help.

Headache. Track timing relative to application. Headache occurring 12-24 hours after application may reflect a serum estradiol peak. Discuss splitting the dose with your clinician (not standard dosing, but sometimes used off-label) or switching to a lower-dose formulation.

Application-site reactions. Rotate sites. Switch gel base (Divigel to Elestrin or vice versa). If reaction is severe, consider a patch or estradiol spray.

Breakthrough bleeding. In women with a uterus on combined estrogen-progestogen therapy, give it 3-6 months. Persistent or heavy bleeding warrants endometrial evaluation (transvaginal ultrasound, possible biopsy).

Any new symptom that concerns you in the first weeks of starting estradiol gel deserves a message to your clinician rather than waiting for an annual visit. Dose adjustments early in therapy prevent unnecessary discontinuation.